凝集素樣氧化低密度脂蛋白受體1(LOX1)多克隆抗體
Polyclonal Antibody to Lectin Like Oxidized Low Density Lipoprotein Receptor 1 (LOX1)
OLR1; CLEC8A; SCARE1; Oxidized low-density lipoprotein receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; Lectin-type oxidized LDL receptor 1
- 編號(hào)PAB859Rb51
- 物種Oryctolagus cuniculus (Rabbit，兔)相同的名稱，不同的物種。
- 來(lái)源多抗制備
- 宿主豚鼠
- 效價(jià)-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物別藻藍(lán)蛋白
- 免疫原-
- 緩沖液成份磷酸鹽緩沖液（pH7.4, 含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格20μl100μl200μl1ml10ml
- 價(jià)格¥ 652¥ 1520¥ 2172¥ 5430¥ 21720
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
DAB staining on IHC-P; Samples: Rabbit Pancreas Tissue; Primary Ab: 10μg/ml Cavia Anti-Rabbit LOX1 Antibody Second Ab: 2μg/mL?HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody (Catalog: SAA544Gu09)
DAB staining on IHC-P;
Samples: Rabbit Kidney Tissue;
Primary Ab: 10μg/ml Cavia Anti-Rabbit LOX1 Antibody
Second Ab: 2μg/mL?HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody
(Catalog: SAA544Gu09)
DAB staining on IHC-P;
Samples: Rabbit Cardiac Muscle Tissue;
Primary Ab: 10μg/ml Cavia Anti-Rabbit LOX1 Antibody
Second Ab: 2μg/mL?HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody
(Catalog: SAA544Gu09)
Western Blot; Samples: Lane1: Rabbit Lung lysate; Lane2: Rabbit Heart lysate; Primary Ab: 0.1μg/ml Cavia Anti-Rabbit LOX1 Antibody Second Ab: 0.2μg/ml HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody (Catalog: SAA544Gu09)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)LOX1的豚鼠多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別LOX1。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學(xué)：5-20μg/mL;1:25-100
免疫細(xì)胞化學(xué)：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB859Rb01 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB859Rb51 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)多克隆抗體 | WB; IHC |
| PAB859Rb01 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)多克隆抗體 | WB; IHC; ICC; IP. |
| MAB859Rb21 | 凝集素樣氧化低密度脂蛋白受體1(LOX1)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB859Rb | 凝集素樣氧化低密度脂蛋白受體1(LOX1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB859Rb | 凝集素樣氧化低密度脂蛋白受體1(LOX1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinical Cardiology | Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Associated With Angiographic Coronary Lesion Complexity in Patients With Coronary Artery Diseas[PubMed: 21400544] |
| Coronary Artery Disease | Postprocedural serum sLOX-1 levels are associated with coronary in-stent restenosis in patients with stable coronary artery disease[LWW: 06000] |
| Clinical Biochemistry | Soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in synovial fluid are correlated with disease severity of knee osteoarthritis[ScienceDirect: S0009912011004905] |
| Mediators of Inflammation | Pregnancy Followed by Delivery May Affect Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels in Women of Reproductive Age[PubMed: 22619487] |
| Dicle Medical Journal | Lectin-like oxidized low density lipoprotein receptor 1(LOX-1) levels and endothelial dysfunction in patients with primary essential hyperhidrosis/Primer esansiyel hiperhidroz hastalarinda lektin benzeri okside düsük dansiteli lipoprotein reseptor 1(LOX-1) düzeyleri ve endotel disfonksiyonu[Readperiodicals: Source] |
| Journal of Clinical Laboratory Analysis | Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome[Pubmed:24798146] |
| Journal of Human Hypertension | Endothelial damage in white coat hypertension: role of lectin-like oxidized low-density lipoprotein-1[Pubmed:25007999] |
| Gynecologic and Obstetric Investigation | Inhibition of Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Protects against Plasma/Hypoxia-Mediated Trophoblast Dysfunction Associated with Preeclampsia[Pubmed:25633310] |
| World J Gastroenterol | Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease[PubMed: 26185381] |
| Genetic Testing and Molecular Biomarkers | Serum sLOX-1 Levels Are Correlated with the Presence and Severity of Obstructive Sleep Apnea[PubMed: 25825846] |
| Neurotoxicology. | 27-Hydroxycholesterol regulates cholesterol synthesis and transport in C6 glioma cells.[pubmed:28167099] |
| Journal of the American?Heart?Association | Increased Levels of Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor‐1 in Ischemic Stroke and Transient Ischemic Attack[Pubmed:29330254] |
| Higher serum lectin-like oxidized low-density lipoprotein receptor-1 in patients with stable coronary artery disease is associated with major adverse?…[] | |
| Disease Markers | Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous?…[Pubmed: 31772687] |
| Reproductive Biology | Polycystic ovary syndrome and endothelial dysfunction: A potential role for soluble lectin-like oxidized low density lipoprotein receptor-1[Pubmed: 32409108] |
| Int J Cancer | The oxidized‐LDL/LOX‐1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells[Pubmed:35608341] |